The UK and US have concluded a landmark trade agreement that will preserve no levies on UK pharmaceutical products entering the American market.
Key Provisions of the Pact
Under the terms of the agreement, the UK has pledged to boost funding on pharmaceuticals through the public health system. This pledge guarantees that import taxes on these key exports will stay at zero for a timeframe of 36 months.
This deal is in response to earlier warnings to significantly raise duties on patented drug products, with potential rates discussed as high as double the cost.
"This arrangement with the UK reinforces the global environment for cutting-edge drugs and introduces long-overdue balance to U.S.–U.K. medicine commerce," a release said.
Commercial Importance
Drugs represent one of the UK's most significant exports to the United States, which is by far the largest buyer for major UK drugmakers.
Trade data reveal that in the year prior to the third quarter, the UK sold medicines valued at £11.1bn to the US. This figure represented a significant portion of British export trade in that period.
"This agreement secures work, stimulates capital expenditure and facilitates the UK to emerge as a international leader for medical research," a government official commented.
Specific NHS Changes
The pact involves several key changes from the United Kingdom:
- Higher Cost Ceiling: The UK will increase the price threshold at which it deems new medicines to be too expensive by 25%.
- Increased NHS Spending: There is a target to increase overall NHS spending on drugs from 0.3 percent of GDP to 0.6% over the next decade.
- Payback Limit: The percentage drug companies must pay back to the NHS to prevent overspending will be capped at 15%. Last year, repayments were more than twenty percent.
Broader Context
The deal follows a protracted tension between the pharmaceutical industry and the ministers over medicine costs and approval rates.
This friction were exacerbated by claims that American consumers were charged several times more for the equivalent treatments than patients in the UK and Europe.
Over the last 18 months, several large drug company projects in the UK have been delayed or scrapped, while multi-billion-dollar funding commitments have been pledged toward US facilities.
A senior figure publicly accepted that the NHS needed to increase expenditure on drugs, noting that its expenditure on drugs had decreased as a proportion of its overall budget over the previous ten-year period.
